Trials / Withdrawn
WithdrawnNCT03545087
A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
Pharmacokinetics of Lanabecestat (LY3314814) in Subjects With Impaired Renal Function
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to determine whether lanabecestat can be safely prescribed in participants with kidney impairment without a dose adjustment. Participants will be on study for up to 6 weeks; this includes a 2-week screening and a follow-up about 10 days after final drug administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanabecestat | Administered orally |
| DRUG | Iohexol | Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment. |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2018-06-04
- Last updated
- 2018-06-28
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03545087. Inclusion in this directory is not an endorsement.